Latest news
Adneuris licenses cebranopadol to Maruishi in second ex-US deal within four weeks - AllSciAllSci · Wed, 05 Aug 2026 14:51:55 GMTAdneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 12:30:00 GMT